Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms RESCUE
- 29 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 29 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 31 Aug 2018 Biomarkers information updated